Prelude Therapeutics Inc financial data

Symbol
PRLD on Nasdaq
Industry
Pharmaceutical Preparations
Location
175 Innovation Boulevard, Wilmington, DE
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 766 % -37.8%
Debt-to-equity 24 % +114%
Return On Equity -74.7 % -39.9%
Return On Assets -60.3 % -25.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55.2M shares +0.41%
Entity Public Float 66.1M USD -14.3%
Weighted Average Number of Shares Outstanding, Basic 75.8M shares +25.6%
Weighted Average Number of Shares Outstanding, Diluted 75.8M shares +25.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3M USD
Research and Development Expense 118M USD +14.1%
General and Administrative Expense 28.7M USD -0.57%
Operating Income (Loss) -140M USD -5.62%
Net Income (Loss) Attributable to Parent -127M USD -4.38%
Earnings Per Share, Basic -1.68 USD/shares +16.8%
Earnings Per Share, Diluted -1.68 USD/shares +16.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12.5M USD -50.7%
Marketable Securities, Current 121M USD -41.7%
Assets, Current 136M USD -42.3%
Property, Plant and Equipment, Net 6.77M USD -7.62%
Operating Lease, Right-of-Use Asset 28.7M USD -5.63%
Assets 176M USD -36.8%
Accounts Payable, Current 7.73M USD +68.8%
Employee-related Liabilities, Current 9.02M USD -1.47%
Accrued Liabilities, Current 15.2M USD -3.55%
Liabilities, Current 25.6M USD +17.5%
Operating Lease, Liability, Noncurrent 15.3M USD -0.53%
Other Liabilities, Noncurrent 3.09M USD -7.46%
Liabilities 44.1M USD +8.58%
Accumulated Other Comprehensive Income (Loss), Net of Tax 35K USD -84.3%
Retained Earnings (Accumulated Deficit) -584M USD -27.9%
Stockholders' Equity Attributable to Parent 131M USD -44.6%
Liabilities and Equity 176M USD -36.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.8M USD -5.5%
Net Cash Provided by (Used in) Financing Activities -269K USD -101%
Net Cash Provided by (Used in) Investing Activities 31.2M USD +73.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -584K USD +95.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.5M USD -43.7%
Deferred Tax Assets, Valuation Allowance 183M USD +23.7%
Deferred Tax Assets, Gross 188M USD +23%
Operating Lease, Liability 17.8M USD
Payments to Acquire Property, Plant, and Equipment 289K USD -64.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -127M USD -6.21%
Lessee, Operating Lease, Liability, to be Paid 41.4M USD
Property, Plant and Equipment, Gross 12M USD +10.4%
Operating Lease, Liability, Current 2.49M USD +68.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.97M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 2.71M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 23.6M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.05M USD
Deferred Tax Assets, Operating Loss Carryforwards 81.5M USD +13.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.12M USD
Operating Lease, Payments 0 USD -100%
Depreciation, Depletion and Amortization 426K USD +53.2%
Deferred Tax Assets, Net of Valuation Allowance 5.02M USD +0.04%
Share-based Payment Arrangement, Expense 21.3M USD -16.7%